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The inhibitor of growth (ING) family proteins have been defined as candidate tumor suppressors. ING4 as a novel member of the
ING family has potential tumor-suppressive effects. In this study, we explored the combined effect of adenovirus-mediated ING4
(Ad-ING4) gene transfer plus chemotherapy drug cisplatin (CDDP) on SMMC-7721 human hepatocarcinoma cells in vitro and
in vivo, and its underlying mechanism. We demonstrated that Ad-ING4 plus CDDP induced synergistic growth inhibition,
enhanced apoptosis, and had an additive effect on upregulation of Fas, Bax, Bak, cleaved Bid, cleaved caspase-8, caspase-9,
caspase-3 and cleaved PARP, and on downregulation of Bcl-2 and Bcl-XL in SMMC-7721 hepatocarcinoma cells. Moreover,
Ad-ING4 plus CDDP synergistically suppressed in vivo SMMC-7721 hepatocarcinoma subcutaneous (s.c.) xenografted tumor
growth and reduced tumor vessel CD34 expression and microvessel density (MVD) in athymic nude mice. Most importantly,
Ad-ING4 plus CDDP did not have overlapping toxicities in HL-7702 normal human liver cells and normal liver tissues of mice. The
in vitro and in vivo enhanced antitumor effect elicited by Ad-ING4 plus CDDP was closely associated with the cooperative
regulation of extrinsic and intrinsic apoptotic pathways and synergistic inhibition of tumor angiogenesis. Thus, our results indicate
that Ad-ING4 plus CDDP is a potential combined treatment strategy for hepatocarcinoma.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most
common cancer in the world, and is the third highest
cause of cancer-related mortality.
1 The incidence is
increasing worldwide because of the dissemination of
hepatitis B and C virus infection.
2,3 Surgical resection is
the mainstay of curative treatment for early HCC, but
prognosis remains unsatisfactory because of frequent
recurrence.
4 Liver transplantation is another potentially
curative treatment for HCC, but its application is limited
by the shortage of grafts.
5 For unresectable HCC, various
locoregional therapies may be used to palliate symptoms
and prolong survival.
6 Furthermore, conventional
chemotherapy has not been shown to be effective in
HCC, and there is no proven effective systemic therapy
for HCC patients with metastatic disease.
7 Hence, the
search for novel therapeutic modalities for HCC is of
paramount importance.
Cancer gene therapy represents a new and promising
therapeutic modality for cancers, which is based on the
introduction of genetic material into cells to generate a
curative biological effect. A variety of gene therapy-based
anticancer strategies have been effective in animal tumor
models, including replacement of tumor suppressor genes,
selective activation of prodrugs, genetic immunotherapy
and antiangiogenic actions. Inhibitor of growth 4 (ING4),
a novel member of the ING tumor suppressor family,
was first isolated and characterized by Shiseki et al.
8
Recently, ING4 has attracted much attention as a strong
candidate tumor suppressor that has an important role in
oncogenesis, DNA repair, tumor growth, angiogenesis,
migration and gene transcription regulation. ING4 has a
functionally conserved plant homeodomain-finger motif
in the COOH-terminal region involved in chromatin
remodeling and subsequent gene transcriptional regula-
tion by its interaction with histone acetyltransferase
and histone deacetylase complexes.
9–11 It also has a
potential bipartite nuclear localization signal domain in
the middle region, which is essential for nuclear localiza-
tion of ING4 and its binding and functional interaction
with p53.
12 Previous studies showed that ING4 was
dramatically downregulated in glioblastoma,
13 head and
neck carcinoma,
14 HCC,
15 melanoma
16,17 and gastric
carcinoma,
18 which was closely associated with tumor
grade, metastasis and prognosis. ING4 can significantly
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www.nature.com/cgtinhibit tumor cell growth and induce cell cycle alteration
and apoptosis in different tumor types
8,13,16,17,19–22 such
as colorectal, glioblastoma, melanoma, hepatocellular,
myeloma, lung and pancreatic carcinomas, and enhance
chemosensitivity to doxorubicin and etoposide in HepG2
hepatocarcinoma cells.
19 ING4 can also suppress the
activity of NF-kB and HIF-1a, leading to inhibition of
tumor angiogenesis.
13,20 In addition, ING4 can suppress
the loss-of-contact inhibition elicited by MYCN or
MYC.
23 More recently, it has been reported that ING4
can exhibit a marked inhibitory effect on tumor cell
spreading, migration and invasion.
16,21,24 Therefore,
ING4 is a potent tumor suppressor that exerts its
tumor-suppressive effect via multiple pathways in a
variety of tumors.
Chemotherapy is one of the most conventional
therapeutic strategies for human cancers. Conventional
chemotherapy drugs include cisplatin, also named cis-
diamminedichloroplatinum (CDDP), adriamycin and
5-fluorouracil. CDDP is deemed to be the ‘penicillin of
cancer drugs’ because of its universal, early and effective
treatment for many cancers.
25 Unlike many anticancer
drugs, CDDP is an inorganic molecule with a simple
structure that is often used as an attractive chemotherapy
drug and broadly used for the treatment of various forms
of malignant tumors. Although the mechanism has not
yet been fully understood, CDDP is generally believed to
kill cancer cells by binding to DNA and interfering with
the cell’s repair mechanism, which eventually leads to cell
death.
26 Despite these merits, severe toxic side effects and
drug resistance that limit its efficacy are major clinical
obstacles associated with CDDP-based chemother-
apy.
27,28 Thus, it is urgent to explore novel approaches
to reduce drug dosage, minimize side effects and enhance
therapeutic efficacy to promote the application of CDDP
in cancer chemotherapy.
Combination therapy with multiple drugs or modalities
such as the combined treatment of gene therapy and
conventional chemotherapy (chemo-gene therapy) or
radiotherapy is a common practice in the treatment of
cancers, which can achieve greater therapeutic benefit and
reduce the side effects and resistance to drugs.
29,30
Interestingly, the tumor suppressor ING4 can sensitize
HepG2 hepatocarcinoma cells to DNA-damaging agents
such as doxorubicin and etoposide,
19 suggesting that it
may be used as a chemosensitive modulator in the
combination therapy with chemotherapy drugs for
cancers. Therefore, we hypothesized that a combination
of adenovirus-mediated ING4 (Ad-ING4) gene transfer
and chemotherapy drug CDDP would exhibit an enhan-
ced antitumor activity for human cancers. To date, the
therapeutic effect of the conjugation of Ad-ING4 with
CDDP on human cancers has not been reported. To
enhance the therapeutic efficacy and develop a novel
combination therapeutic modality for HCC, in this study,
we investigated the potential combined effect of Ad-ING4
plus CDDP against SMMC-7721 human hepatocarcino-
ma cells in vitro and in vivo in an athymic nude mouse
model, and also elucidated its underlying molecular
mechanism.
Materials and methods
Adenoviruses, cell lines, reagents and mice
The Ad-ING4 and Ad-green fluorescent protein (GFP)
replication-incompetent Ad5E1- and E3-deleted adeno-
viruses were constructed in our laboratory,
21 Cell and
Molecular Biology Institute, College of Medicine,
Soochow University (Suzhou, China). The QBI-293A
human embryonic kidney cell line was kindly provided by
Prof. Jiang Zhong, Fudan University (Shanghai, China).
The SMMC-7721 and HepG2 human hepatocarcinoma
cell lines and HL-7702 normal human liver cells were
purchased from the American Type Culture Collection
(ATCC) (Shanghai, China). The QBI-293A, SMMC-
7721, HepG2 and HL-7702 cells were cultured in
RPMI1640 (GIBCO, Shanghai, China) supplemented
with 10% fetal bovine serum (Hyclone, Shanghai, China),
respectively. Trizol was purchased from Invitrogen
(Shanghai, China). The reverse transcriptase polymerase
MuMLV was purchased from MBI (Shanghai, China).
The polyclonal goat anti-ING4 antibody was purchased
from Abcam (Shanghai, China). The CDDP was kindly
provided by Dr Yehan Zhu, the first hospital affiliated
to Soochow University (Suzhou, China). The 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
kit was purchased from Sigma (Shanghai, China). The
Annexin V-PE/7-AAD apoptosis detection kit was
purchased from BD Biosciences (Shanghai, China). The
antibodies specific for Fas, Bcl-2, Bcl-XL, Bax, Bak,
b-actin and CD34 were purchased from Santa Cruz
(Shanghai, China). The antibodies specific for Bid,
caspase-3, caspase-8, caspase-9 and PARP were pur-
chased from Cell Signaling (Shanghai, China). The
SuperEnhanced chemiluminescence detection kit was
purchased from Applygen Technologies Inc. (Beijing,
China). The UltraSensitiveTM SP kit was purchased from
Maixin (Fuzhou, China). The mouse alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST)
enzyme-linked immunosorbent assay (ELISA) kits were
purchased from Uscn Life Science (Wuhan, China). The
female athymic nude mice were purchased from Shanghai
Experimental Animal Center (Shanghai, China) and
maintained in the animal facility at Soochow University
according to the animal research committee’s guidelines
of Soochow University.
Analysis of adenoviral infection efficiency and ING4
transgene expression
The recombinant replication-incompetent Ad5E1- and
E3-deleted adenovirus with two independent cytomega-
lovirus promoters driving ING4 and GFP expression,
Ad-ING4 and its control adenovirus Ad-GFP expressing
GFP under the control of cytomegalovirus promoter
were prepared as described previously.
21 The titer of
Ad-ING4 and Ad-GFP adenoviruses was determined using
the gene transfer unit (GTU) method by calculating the
number of the reporter gene GFP-expressing QBI-293A cells
under fluorescence microscopy within 18h after adenoviral
infection. To assess the optimal ratio of infectious
adenovirus (GTU) to target cells, called multiplicity of
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expression in SMMC-7721, HepG2 and HL-7702 cells,
the SMMC-7721 and HepG2 human hepatocarcinoma
cells and HL-7702 normal human liver cells were infected
with Ad-GFP and Ad-ING4 at various MOIs (0, 1, 10,
25, 50, 100 and 200), respectively. The adenoviral
infection efficiency was examined according to GFP
expression by fluorescence microscopy. Furthermore,
the ING4 transgene expression mediated by adenoviral
infection in SMMC-7721 and HepG2 human hepatocar-
cinoma cells and HL-7702 normal human liver cells was
determined by reverse transcriptase-PCR and western
blot analysis. Total cellular RNAs were extracted from
Ad-ING4- or Ad-GFP-infected and uninfected SMMC-
7721, HepG2 and HL-7702 cells using Trizol, and first-
strand complementry DNA was reversely transcribed
with RNA as template and oligo d(T)18 as primer. The
PCR reaction was carried out using complementry DNA
as template and ING4-F (50-GCGTCGACATGGATGA
TGGGATGTATTTGGAAC-30) and ING4-R (50-GCAA
GCTTCTATTTCTTCTTCCGTTCTTGGGAG-30)a s
primers under the conditions 1 cycle at 941C (2min)
and then 721C (10min) followed by 35 cycles at 941C
(50s), 581C (50s) and 721C (55s). All PCR reaction
products were analyzed on 1% agarose gel electrophoresis
with ethidium bromide staining. Total cellular lysates
derived from Ad-ING4 or Ad-GFP-infected and unin-
fected SMMC-7721, HepG2 and HL-7702 cells were
resolved by 12% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and subsequently trans-
ferred onto a polyvinylidene difluoride membrane. The
membrane was blocked by incubation with 5% (w/v) non-
fat dry milk in Tris-buffered saline containing 0.05%
Tween 20 (TBST) for 1h at 371C. For western blot
analysis, the membrane was incubated with primary
antibody polyclonal goat anti-ING4 (1:1000) in blocking
solution for 1h at 371C. The membrane was washed with
TBST and incubated with peroxidase horseradish perox-
idase-conjugated secondary antibody rabbit anti-goat IgG
(1:3000) in blocking solution for another 1h at 371C. The
membrane was then washed and developed by use of a
SuperEnhanced chemiluminescence detection kit. The
protein bands were visualized after exposure of the
membranes to Kodak X-ray film.
Cell viability assay
To assess the cytotoxic effect of Ad-ING4 or CDDP
alone on SMMC-7721, HepG2 and HL-7702 cells, the
SMMC-7721 and HepG2 human hepatocarcinoma cells
and HL-7702 normal human liver cells were dispensed in
a 96-well culture plate at a density of 1 10
4 cells per well,
respectively, and incubated at 371C. After 24-h incuba-
tion, the SMMC-7721, HepG2 and HL-7702 cells were
treated with Ad-ING4 at the optimal MOIs, 50 (SMMC-
7721), 25 (HepG2) and 25 (HL-7702), or various doses of
CDDP (0.75, 1.5, 3, 6 or 12mgml
 1) for 3 days, respec-
tively. The medium containing Ad-GFP was used as a
blank adenovirus control, whereas the medium containing
phosphate-buffered saline (PBS) without Ad-ING4,
Ad-GFP or CDDP was used as a cell control (PBS
control). At 3 days after treatment, the SMMC-7721,
HepG2 and HL-7702 cells were incubated with 10ml MTT
(5mgml
 1) for 4h at 371C. The formazan crystals in the
cells were solubilized with stop solution and the plate was
then read at 570nm using a Microplate Reader Model 550
(BIO-RAD, Shanghai, China). To further determine the
combined effect of Ad-ING4 and CDDP on hepatocarci-
noma cells, the SMMC-7721 hepatocarcinoma cells, a
relatively non-sensitive hepatocarcinoma cell line to
chemotherapy drug CDDP, and an optimal dose of
1.5mgml
 1 of CDDP were employed in the in vitro
combination therapy studies. Briefly, the SMMC-7721
human hepatocarcinoma cells were dispensed in a 96-well
culture plate at a density of 1 10
4 cells per well and
incubated at 371C. After 24-h incubation, the SMMC-
7721 hepatocarcinoma cells were treated with Ad-ING4
(50 MOI), Ad-GFP (50 MOI) or CDDP (1.5mgml
 1)
alone, Ad-ING4 (50 MOI) plus CDDP (1.5mgml
 1), or
Ad-GFP (50 MOI) plus CDDP (1.5mgml
 1) for the
indicated time periods (0–4 days). The medium containing
PBS without Ad-ING4, Ad-GFP, CDDP, Ad-ING4
plus CDDP, or Ad-GFP plus CDDP was used as a cell
control (PBS control). To investigate whether Ad-ING4
combined with CDDP exhibits overlapping inhibitory
effect on normal liver cells, the HL-7702 normal human
liver cells were used as a normal liver cell control by
treatment with Ad-ING4 (25 MOI), Ad-GFP (25 MOI)
or CDDP (1.5mgml
 1) alone, Ad-ING4 (25 MOI) plus
CDDP (1.5mgml
 1), Ad-GFP (25 MOI) plus CDDP
(1.5mgml
 1), or PBS. Before treatment and at different
time points after treatment, the viability of HL-7702
normal liver cells was assessed by MTT assay as described
above.
Flow-cytometric analysis of apoptosis
Ad-ING4 plus CDDP-induced apoptosis in SMMC-7721
human hepatocarcinoma cells was assessed by flow
cytometric analysis using Annexin V-PE/7-AAD double
staining following the manufacturer’s instructions.
Briefly, the SMMC-7721 tumor cells (1 10
6) were
treated with Ad-ING4 (50 MOI), Ad-GFP (50 MOI) or
CDDP (1.5mgml
 1) alone, Ad-ING4 (50 MOI) plus
CDDP (1.5mgml
 1), or Ad-GFP (50 MOI) plus CDDP
(1.5mgml
 1). The medium containing PBS without
Ad-ING4, Ad-GFP, CDDP, Ad-ING4 plus CDDP, or
Ad-GFP plus CDDP was used as a cell control (PBS
control). After 24h, the treated and untreated SMMC-7721
t u m o rc e l l sw e r ec o l l e c t e da n dw a s h e dw i t hc o l dP B S ,
respectively. Then the cells (1 10
5) were suspended in
100mlo f1   binding buffer and incubated with 5ml
Annexin V-PE and 5ml 7-AAD at room temperature.
After 15-min incubation, 400mlo f1  binding buffer was
added and the apoptotic cells were analyzed by flow
cytometry.
Western blot analysis
The SMMC-7721 human hepatocarcinoma cells were
treated with Ad-ING4 (50 MOI), Ad-GFP (50 MOI) or
CDDP (1.5mgml
 1) alone, Ad-ING4 (50 MOI) plus
CDDP (1.5mgml
 1) or Ad-GFP (50 MOI) plus CDDP
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 1). The medium containing PBS without
Ad-ING4, Ad-GFP, CDDP, Ad-ING4 plus CDDP or
Ad-GFP plus CDDP was used as a cell control (PBS
control). After 24-h treatment, the treated and untreated
SMMC-7721 tumor cells were collected, washed with cold
PBS and lysed in lysis buffer (1 10
7 cells per 1ml lysis
buffer). Total cellular proteins were extracted and the
protein concentration was determined by BCA protein
assay using a spectrophotometer. To elucidate the
molecular mechanism involved in Ad-ING4 plus
CDDP-induced enhancement of growth inhibition and
apoptosis in SMMC-7721 hepatocarcinoma cells, the
cellular lysates containing 100mg of total protein were
subjected to western blot analysis as described above
using primary antibodies specific for Fas, caspase-8, Bid,
Bcl-2, Bcl-XL, Bax, Bak, caspase-9, caspase-3 and PARP,
respectively.
Animal studies
Female athymic nude mice were subcutaneously (s.c.)
inoculated on the armpits of their right anterior limbs
with 2 10
6 SMMC-7721 human hepatocarcinoma cells,
and then monitored daily for tumor growth. Tumor
volume was measured with a caliper and calculated by the
formula, tumor size¼ab
2/2, where a is the larger and b is
the smaller of the two dimensions. When the tumors grew
up to a mean tumor volume of around 0.2–0.3cm
3,
SMMC-7721 human hepatocarcinoma s.c. xenografted
tumor-bearing mice were subjected to in vivo CDDP-dose-
finding study and Ad-ING4 plus CDDP combination
treatment, respectively. In the CDDP-dose study, tumor-
bearing mice (three mice each group) were intraperitone-
ally (i.p.) injected with various doses of CDDP (1, 3, 5 or
10mgkg
 1 body weight) or PBS every other day for a
total of five times. Tumor volume and body weight were
monitored over time. According to the preliminary
CDDP-dose pilot study, an optimal dose of 1mgkg
 1
of CDDP was selected for the subsequent Ad-ING4 plus
CDDP in vivo combination treatment. In the in vivo
combination treatment, tumor-bearing mice were ran-
domly divided into six groups (six mice each group) and
intratumorally injected with Ad-ING4 (1 10
8 GTU),
Ad-GFP (1 10
8 GTU) or PBS alone, or i.p. injected with
CDDP (1mgkg
 1) alone or plus Ad-ING4 (1 10
8 GTU)
or Ad-GFP (1 10
8 GTU) by intratumoral injection
every other day for a total of five times, respectively.
Tumor progression and body weight were monitored
daily. In addition, the tumor-bearing mice were killed 3
weeks after single or combination treatment, and
the SMMC-7721 hepatocarcinoma s.c. xenografted tu-
mors and normal liver tissues of mice were removed,
weighted, fixed by 10% neutral formalin and embedded in
paraffin for hematoxylin and eosin staining and immuno-
histochemistry analysis, respectively. On the day of
euthanization, blood samples were also collected by tail
veil breeding for measurement of liver serum enzymes
such as ALT and AST by ELISA using mouse ALT and
AST ELISA kits according to the manufacturer’s
instructions.
CD34 immunostaining and microvessel density (MVD)
counting
The expression of CD34 in SMMC-7721 human hepato-
carcinoma xenografted tumors was tested by immuno-
histochemistry analysis using an UltraSensitiveTM SP kit.
The presence of buffy or brown diaminobenzidine
precipitates is indicative of positive reactivity for CD34.
MVD, detected by immunostaining for CD34, was
determined as previously described by Weidner et al.
31
Any endothelial cell cluster immunoreactive for CD34
clearly separated from adjacent microvessels was con-
sidered as a single countable vessel. Each value represents
the number of vessels counted at a high-power view
( 400) by microscopy. The mean value represents the
average number derived from five high-power fields of
each case.
Calculation of synergistic indexes
The interactive effects of Ad-ING4 and CDDP were
evaluated by combination index (CI) calculated by the
formula as described previously,
32 CI¼FuAFuB/
Fu(AþB), where FuA represents the fraction unaffected
by Ad-ING4 alone compared with the untreated control
group, FuB represents the fraction unaffected by CDDP
alone, and Fu(AþB) represents the fraction unaffected
by Ad-ING4 plus CDDP. A value of CI 41 indicates a
synergistic effect between Ad-ING4 and CDDP, and CI
o1 indicates a less than additive effect.
Statistical analysis
All data are presented as the mean±s.d. The significance
of the difference between groups was evaluated by one-
way and two-way repeated-measures analysis of variance
(ANOVA), multiple comparisons and Student’s t test with
SPSS 10.0 software. A value of Po0.05 was considered
statistically significant.
Results
Ad-ING4 transgene expression
To determine the optimal MOI for a maximal infection
and transgene expression, the SMMC-7721 and HepG2
hepatocarcinoma cells and HL-7702 normal liver cells
were infected with Ad-GFP and Ad-ING4 at various
MOIs (0, 1, 10, 25, 50, 100 and 200), respectively, and
examined by fluorescence microscopy. More than 90% of
GFP expression was found in the Ad-GFP- or Ad-ING4-
infected SMMC-7721, HepG2 and HL-7702 cells at MOIs
of 50, 25 and 25 or above, respectively, whereas the GFP
expression was not found in the uninfected SMMC-7721,
HepG2 and HL-7702 control cells (data not shown).
Therefore, we selected an MOI of 50, 25 and 25,
respectively, as an optimal dose for adenoviral infection
of SMMC-7721, HepG2 and HL-7702 cells in the
following experiments. To assess Ad-ING4 transgene
expression, the total cellular RNAs and lysates extracted
from Ad-ING4- or Ad-GFP-infected and uninfected
SMMC-7721, HepG2 and HL-7702 cells were subjected
to reverse transcriptase-PCR and western blot analysis.
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expression was found in the Ad-ING4-infected SMMC-
7721, HepG2 and HL-7702 cells, but not in the Ad-GFP-
infected and uninfected SMMC-7721, HepG2 and
HL-7702 control cells, indicating that transgene ING4
mediated by adenovirus is expressed in Ad-ING4-infected
SMMC-7721, HepG2 and HL-7702 cells at both the
transcriptional and translational levels. In addition,
chemotherapy with CDDP did not affect adenoviral
infection and Ad-ING4 expression in the combination
treatment (data not shown).
Ad-ING4 or CDDP alone inhibits in vitro
hepatocarcinoma cell growth
Before initiating the experiment involving a combination
of Ad-ING4 and CDDP, we assessed the effect of
Ad-ING4 or CDDP alone on the viability of SMMC-7721
and HepG2 hepatocarcinoma cells and HL-7702 normal
liver cells, respectively. The SMMC-7721, HepG2 and
HL-7702 cells were treated with Ad-ING4 at the optimal
MOIs of 50, 25 and 25, respectively, or various doses of
CDDP (0.75, 1.5, 3, 6 or 12mgml
 1), and the cell growth
was examined at day 3 after treatment using MTT assay.
As shown in Figure 2a, Ad-ING4 treatment significantly
inhibited SMMC-7721 hepatocarcinoma cell growth
(35% reduction compared with viability of control cells),
whereas it moderately inhibited HepG2 hepatocarcinoma
cell growth (21% reduction), compared with the Ad-GFP-
and PBS-treated control group (Po0.05). However,
Ad-ING4 had minimal effect on HL-7702 normal liver
cells (7% reduction). These results indicated that ING4
transgene overexpression exerts selective killing activity
for tumor cells such as hepatocarcinoma cells. Treatment
of SMMC-7721 and HepG2 hepatocarcinoma cells and
HL-7702 normal liver cells with various concentrations of
CDDP resulted in a dose-dependent reduction in the
number of viable cells (Figure 2b). Furthermore, SMMC-
7721 and HepG2 hepatocarcinoma cells and HL-7702
normal liver cells are different in their sensitivity to
chemotherapy drug CDDP. The moderate reduction in
SMMC-7721 hepatocarcinoma cell viability was observed
at 1.5mgml
 1 of CDDP (19% reduction), and significant
reduction was observed starting at 3mgml
 1 (37%
reduction), with maximum reduction observed at
12mgml
 1 (69% reduction). Unexpectedly, the significant
reduction in HepG2 hepatocarcinoma cell viability was
observed starting at the lowest concentration of CDDP
(0.75mgml
 1) (49% reduction), with maximum reduction
observed at 12mgml
 1 (89% reduction). However, the
significant reduction in HL-7702 normal liver cell viability
was observed at 6 (29% reduction) and 12mgml
 1 (47%
reduction), with slight reduction observed at 3mgml
 1
(14% reduction). These results indicated that HepG2
hepatocarcinoma cells are much more sensitive to
chemotherapy drug CDDP than SMMC-7721 hepatocar-
cinoma cells, and only a higher concentration of CDDP
ranging from 6 to 12mgml
 1 exhibits significant cyto-
toxic effect on HL-7702 normal liver cells. Therefore, we
selected the relatively non-sensitive hepatocarcinoma cell
line to CDDP, SMMC-7721 and the optimal dose of
1.5mgml
 1 of CDDP in the in vitro combination
treatment to minimize toxicity to normal cells and elicit
only modest antitumor activity when used as single
therapy, while leaving a window for observation of the
additive or synergistic effects of Ad-ING4 plus CDDP
combination therapy.
Ad-ING4 plus CDDP synergistically suppresses in vitro
and in vivo SMMC-7721 hepatocarcinoma cell growth
To investigate whether Ad-ING4 plus CDDP elicits
enhanced cytotoxicity to hepatocarcinoma cells in vitro,
the SMMC-7721 human hepotacarcinoma cells were
cultured in the presence of Ad-ING4 (50 MOI), Ad-
GFP (50 MOI) or CDDP (1.5mgml
 1) alone, Ad-ING4
(50 MOI) plus CDDP (1.5mgml
 1), or Ad-GFP (50 MOI)
plus CDDP (1.5mgml
 1). The tumor cell viability was
examined daily for 4 days using MTT assay. As shown in
Figure 3a, Ad-ING4 plus CDDP combination treatment
synergistically inhibited in vitro SMMC-7721 hepatocar-
cinoma cell growth in a time-dependent manner, com-
pared with single Ad-ING4- and CDDP-treated group
(Po0.05; CI41), whereas the phenomenon did not occur
in the Ad-GFP plus CDDP combination treatment,
indicating that it is Ad-ING4 expression that contributes
to the combined suppressive effect on SMMC-7721
hepatocarcinoma cells. Moreover, Ad-ING4 plus CDDP
exhibited minimal cytotoxic effect on HL-7702 normal
liver cells, equal to that of CDDP (Figure 3a). The result
further indicated that Ad-ING4 plus CDDP combination
treatment selectively exerts synergistic antitumor activity
Figure 1 Transgene ING4 expression in Ad-ING4-infected SMMC-
7721, HepG2 and HL-7702 cells. (a) Ad-ING4 transcriptional
expression by reverse transcriptase-PCR analysis. Total cellular
RNAs were obtained from Ad-ING4-infected SMMC-7721 and
HepG2 hepatocarcinoma cells and HL-7702 normal liver cells,
Ad-GFP-infected SMMC-7721, HepG2 and HL-7702 cells served
as a blank adenovirus control, or uninfected SMMC-7721, HepG2
and HL-7702 control cells, respectively. The first-strand comple-
mentry DNA was synthesized from RNAs using reverse transcrip-
tase; PCRs were conducted using primer sets specific for ING4 and
housekeep gene b-actin used as an internal control. (b) Ad-ING4
translational expression by western blot analysis. Total cellular
lysates of Ad-ING4- or Ad-GFP-infected SMMC-7721, HepG2 and
HL-7702 cells and uninfected control cells were analyzed by
immunoblotting with anti-ING4 and anti-b-actin (an internal control)
antibody, respectively. Data shown are representative of three
independent experiments.
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7702 normal liver cells. To determine the optimal dose of
CDDP employed in vivo in an athymic nude mouse
animal model combination treatment, a dose-finding
study was performed in which SMMC-7721 human
hepatocarcinoma s.c. xenografted tumor-bearing mice
(three mice each group) were treated with a range of
CDDPs (1, 3, 5 or 10mgkg
 1) by i.p. injection. Tumor
volume and body weight were monitored over time. Mice
treated with higher doses of CDDP (5 or 10mgkg
 1)
resulted in a significant loss of body weight and had to be
euthanized within a week, whereas those treated with 1 or
3mgkg
 1 of CDDP showed no significant body weight
losses with only minimal toxicity (data not shown).
Compared with the PBS-treated control group, tumor
progression was significantly retarded in the mice treated
with 3mgkg
 1 of CDDP, but moderately retarded in
those treated with 1mgkg
 1 of CDDP (date not shown).
Therefore, an optimal dose of 1mgkg
 1 of CDDP was
selected for the Ad-ING4 plus CDDP in vivo combination
treatment. To further explore whether the combination of
Ad-ING4 with CDDP would result in in vivo-enhanced
antitumor effect, the athymic nude mice (six mice each
group) bearing SMMC-7721 human hepatocarcinoma s.c.
xenografted tumors were intratumorally injected with Ad-
ING4 (1 10
8 GTU), Ad-GFP (1 10
8 GTU) or PBS
alone, or i.p. injected with CDDP (1mgkg
 1) alone or
plus Ad-ING4 (1 10
8 GTU) or Ad-GFP (1 10
8 GTU)
by intratumoral injection every other day for a total of
five times. The tumor growth in vivo was monitored daily
and tumor volume and weight were measured. As shown
in Figure 3b, the tumor growth was more significantly
retarded in the Ad-ING4 plus CDDP group, compared
with the single Ad-ING4- and CDDP-treated group
(Po0.05; CI41), indicating that Ad-ING4 plus CDDP
combination treatment also remarkably suppresses in vivo
SMMC-7721 hepatocarcinoma s.c. xenografted tumor
growth in an athymic nude mouse model with synergistic
effect. To assess Ad-ING4 plus CDDP-mediated in vivo
toxicity, body and liver weight were investigated. As
shown in Figures 3c and d, there was no difference in
body and liver weight among various groups. Histological
Figure 2 Ad-ING4 or CDDP alone suppresses in vitro hepatocarcinoma cell growth. (a) The cytotoxic effect of Ad-ING4 on SMMC-7721 and
HepG2 hepatocarcinoma cells and HL-7702 normal liver cells. The SMMC-7721, HepG2 and HL-7702 cells were treated with Ad-ING4 at MOI of
50, 25 and 25 or with Ad-GFP blank adenovirus or PBS served as controls for 3 days, respectively. The survival cells were evaluated at day 3
point after treatment by using MTT assay. The in vitro growth of SMMC-7721 and HepG2 tumor cells treated with Ad-ING4 was significantly or
moderately inhibited after infection, whereas Ad-ING4 had minimal effect on HL-7702 normal liver cells (*Po0.05, compared with Ad-GFP and
PBS group, one-way repeated measures ANOVA and multiple comparisons, n¼4 replicates per condition). (b) The cytotoxic effect of CDDP on
SMMC-7721 and HepG2 hepatocarcinoma cells and HL-7702 normal liver cells. The SMMC-7721, HepG2 and HL-7702 cells were treated with
various doses of CDDP (0.75, 1.5, 3, 6 or 12mgml
 1) for 3 days, respectively. The survival cells were evaluated at day 3 point after treatment by
using MTT assay. CDDP inhibits in vitro growth of SMMC-7721 and HepG2 hepatocarcinoma cells and HL-7702 normal liver cells in a dose-
dependent manner (*Po0.05, compared with PBS group, Student t test, n¼4 replicates per condition). Data shown are representative of three
independent experiments.
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Cancer Gene Therapysections of liver in different groups also showed no
significant hepatic damage (data not shown). In addition,
ELISA analysis of liver serum enzymes (Figure 3e)
showed a slight increase in ALT and AST elicited by
CDDP, but no additive effect in the Ad-ING4 plus
CDDP group. These results indicated that the combina-
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Cancer Gene Therapytion of Ad-ING4 and CDDP also exhibits minimal
toxicity in vivo without overlapping effect.
Ad-ING4 plus CDDP enhances apoptosis in
SMMC-7721 hepatocarcinoma cells
To examine whether Ad-ING4 plus CDDP combination
treatment elicits enhanced apoptosis in hepatocarcinoma
cells, the SMMC-7721 human hepatocarcinoma cells were
treated with Ad-ING4 (50 MOI), Ad-GFP (50 MOI) or
CDDP (1.5mgml
 1) alone, Ad-ING4 (50 MOI) plus
CDDP (1.5mgml
 1), or Ad-GFP (50 MOI) plus CDDP
(1.5mgml
 1) for 24h and harvested for staining with
Annexin V-PE (early apoptotic marker) and 7-AAD (late
apoptotic marker), and the apoptosis of SMMC-7721
tumor cells was then analyzed by flow cytometry. As
shown in Figure 4a, Ad-ING4 plus CDDP combination
treatment resulted in 32.8% Annexin V single-positive
cells, indicating that these SMMC-7721 hepatocarcinoma
cells are in early stage of apoptosis, whereas there was 1.9,
2.6, 17.5, 10.2 and 11.9% early apoptotic cells occurring
in SMMC-7721 tumor cells grown in the medium with
PBS, Ad-GFP, Ad-ING4, CDDP and Ad-GFP plus
CDDP, respectively. Compared with the single Ad-ING4-
and CDDP-treated group, the combination of Ad-ING4
with CDDP more efficiently induces SMMC-7721 hepa-
tocarcinoma cell apoptosis with synergistic effect
(Po0.05; CI41), which closely correlates with the Ad-
ING4 plus CDDP-mediated in vitro and in vivo synergistic
growth inhibition of SMMC-7721 hepatocarcinoma cells.
Ad-ING4 plus CDDP cooperatively regulates
extrinsic and intrinsic apoptotic pathways
To further address the underlying molecular mechanism
by which Ad-ING4 plus CDDP combination treatment
results in enhanced antitumor effect, the expression of
apoptosis-related proteins such as Fas, caspase-8, Bid,
Bcl-2, Bcl-XL, Bax, Bak, caspase-9, caspase-3 and PARP
in SMMC-7721 human hepatocarcinoma cells with
different treatments was determined by western blot
analysis. As shown in Figure 4b, the expression of Fas,
Bax and Bak in Ad-ING4, CDDP, Ad-GFP plus CDDP,
and Ad-ING4 plus CDDP group was significantly
increased, whereas the expression of Bcl-2 and Bcl-XL
was decreased, compared with the Ad-GFP and PBS
control group. The activation of caspase-8, Bid, caspase-9,
caspase-3 and PARP was also found in Ad-ING4, CDDP,
Ad-GFP plus CDDP, and Ad-ING4 plus CDDP groups,
but not in the Ad-GFP and PBS control group. More-
over, Ad-ING4 plus CDDP combination treatment
elicited an additive effect on the altered expression of
apoptosis-related proteins involved in the activation of
extrinsic and intrinsic apoptotic pathways, indicating that
Ad-ING4 plus CDDP synergistically suppresses SMMC-
7721 hepatocarcinoma cell growth and induces apoptosis
closely associated with the cooperative regulation of
extrinsic and intrinsic apoptotic pathways.
Ad-ING4 plus CDDP synergistically reduces tumor
vessel CD34 expression and MVD
The positive expression of CD34 was mainly represented
as brownish yellow or brownish granules in vascular
endothelial cells. In all SMMC-7721 human hepatocarci-
noma s.c. xenografted tumors collected, the CD34
expression of tumor vascular endothelial cells in the Ad-
ING4 plus CDDP combination treatment group was
weaker or less, compared with the single Ad-ING4- and
CDDP-treated group (Figure 5a), indicating that Ad-
ING4 plus CDDP additively or synergistically down-
regulates CD34 expression of SMMC-7721 human
hepatocarcinoma xenografted tumor vessels. Further-
more, the MVD (Figure 5b) counted in the Ad-ING4
plus CDDP group was significantly lesser than that in the
single Ad-ING4- and CDDP-treated group (Po0.05;
CI41), indicating that Ad-ING4 plus CDDP has an
synergistic effect on reduction of MVD in SMMC-7721
hepatocarcinoma s.c. xenografted tumors, which may
Figure 3 Ad-ING4 plus CDDP elicits synergistic antitumor activity for SMMC-7721 hepatocarcinoma cells without overlapping toxicity. (a)T h e
in vitro combined effect of Ad-ING4 plus CDDP on SMMC-7721 hepatocarcinoma cells or HL-7702 normal liver cells. The SMMC-7721
hepatocarcinoma cells and HL-7702 normal liver cells were treated with Ad-ING4 (50, 25 MOI), Ad-GFP (50, 25 MOI) or CDDP (1.5mgml
 1)a l o n e ,
Ad-ING4 (50, 25 MOI) plus CDDP (1.5mgml
 1), Ad-GFP (50, 25 MOI) plus CDDP (1.5mgml
 1), or PBS for the indicated time periods (0–4 days),
respectively. The survival cells were evaluated at day 0, 1, 2, 3 and 4 point after treatment by using MTT assays. Ad-ING4 plus CDDP combination
treatment synergistically inhibited in vitro SMMC-7721 hepatocarcinoma cell growth in a time-dependent manner (*Po0.05, compared with Ad-GFP
and PBS group at day 1, 2, 3 and 4 after treatment, respectively, two-way repeated measures ANOVA and multiple comparisons, n¼4r e p l i c a t e s
per condition;
# CI in the Ad-ING4 plus CDDP combination treatment 41). In addition, Ad-ING4 plus CDDP exhibited minimal cytotoxic effect on
in vitro HL-7702 normal liver cells equal to that of CDDP. (b)T h ein vivo synergistic antitumor effect on SMMC-7721 hepatocarcinoma s.c.
xenografted tumors by combining Ad-ING4 with CDDP. The athymic nude mice (six mice each group) bearing SMMC-7721 hepatocarcinoma s.c.
xenografted tumors were intratumorally injected with Ad-ING4 (1 10
8 GTU), Ad-GFP (1 10
8 GTU) or PBS alone, or i.p. injected with CDDP
(1mgkg
 1) alone or plus Ad-ING4 (1 10
8 GTU) or Ad-GFP (1 10
8 GTU) by intratumoral injection every other day for a total of five times. The
SMMC-7721 hepatocarcinoma s.c. xenografted tumor volume was measured before and after treatment. Furthermore, the xenografted tumors were
removed 3 weeks after treatment and tumor weight was measured. Ad-ING4 plus CDDP combination treatment also synergistically suppressed in
vivo SMMC-7721 hepatocarcinoma s.c. xenografted tumor growth in an athymic nude mouse model (tumor weight, *Po0.05, compared with Ad-
GFP and PBS group, one-way repeated measures ANOVA and multiple comparisons, n¼6 mice per condition, and tumor volume, *Po0.05,
compared with Ad-GFP and PBS group at week 1, 2 and 3 after treatment, respectively, two-way repeated-measures ANOVA and multiple
comparisons, n¼6 mice per condition;
#CI in the Ad-ING4 plus CDDP combination treatment 4 1). (c, d, e) Ad-ING4 plus CDDP-induced in vivo
toxicity. On the day of the killing mice, body weight (c) and liver weight (d) of mice were measured, and blood samples were collected and the
amounts of ALT and AST liver serum enzymes in serum (e) were assessed by ELISA. There was only a slight increase in ALT and AST derived
from CDDP-induced in vivo toxicity (*Po0.05, compared with PBS group, Student t test, n¼6 mice per condition, n¼3 replicates per sample)
without overlapping effect in Ad-ING4 plus CDDP group. Data shown are representative of three independent experiments.
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Ad-ING4 plus CDDP-mediated in vivo synergistic growth
inhibition of SMMC-7721 hepatocarcinoma xenografted
tumors in an athymic nude mouse model.
Discussion
Recent studies have shown that ING4 as a novel tumor
suppressor is involved in a variety of processes including
oncogenesis, cell cycle control, apoptosis, DNA repair,
angiogenesis, migration and gene transcription regula-
tion. ING4 can significantly inhibit tumor cell growth and
induce cell cycle alteration and apoptosis in a variety of
tumors. ING4 can also suppress brain-tumor angiogen-
esis by inhibiting the activity of NF-kB leading to
transcriptional repression of NF-kB-responsive genes
such as IL-6, IL-8 and Cox-2 by physically interacting
with the p65 subunit of NF-kB.
13 Nozell et al.
33 further
confirmed that ING4 can specifically regulate the activity
Figure 4 Ad-ING4 plus CDDP enhances apoptosis by cooperatively regulating extrinsic and intrinsic apoptotic pathways. The SMMC-7721
hepatocarcinoma cells were treated with Ad-ING4 (50 MOI), Ad-GFP (50 MOI) or CDDP (1.5mgml
 1) alone, Ad-ING4 (50 MOI) plus CDDP
(1.5mgml
 1), Ad-GFP (50 MOI) plus CDDP (1.5mgml
 1), or PBS for 24h, then the apoptotic cells and expression of apoptosis-related proteins in
SMMC-7721 tumor cells were assessed by flow cytometric and western blot analysis, respectively. (a) Ad-ING4 plus CDDP enhances apoptosis
in SMMC-7721 hepatocarcinoma cells. The apoptotic cells were analyzed using Annexin V-PE/7-AAD double staining by flow cytometry. The
Annexin V single-positive cells (early apoptotic cells) in the total cell population represented apoptotic cells. Ad-ING4 plus CDDP enhanced
apoptosis in SMMC-7721 tumor cells with synergistic effect (*Po0.05, compared with Ad-GFP and PBS group, one-way repeated measures
ANOVA and multiple comparisons, n¼3 replicates per condition;
#CI in the Ad-ING4 plus CDDP combination treatment 41). (b) Ad-ING4 plus
CDDP cooperatively regulates extrinsic and intrinsic apoptotic pathways. Total cellular lysates of treated and untreated SMMC-7721 tumor cells
were analyzed by immunoblotting with a panel of antibodies specific for Fas, Caspase-8, Bid, Bcl-2, Bcl-XL, Bax, Bak, Caspase-9, Caspase-3,
PARP and b-actin (an internal control). The quantities of protein expression were normalized to the internal control b-actin measured in the same
samples. Ad-ING4 plus CDDP combination treatment elicited an additive effect on the altered expression of apoptosis-related proteins such as
Fas, Caspase-8, Bid, Bcl-2, Bcl-XL, Bax, Bak, Caspase-9, Caspase-3 and PARP. Data shown are representative of three independent
experiments.
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Cancer Gene Therapyof NF-kB molecules that are bound to target gene
promoters. Furthermore, Colla et al.
20 reported that
ING4 can suppress HIF-1a activity and its target gene
NIP-3 expression in myeloma cells under hypoxic condi-
tion and consequently inhibit tumor angiogenesis. In
addition, ING4 can suppress tumor-cell spreading,
migration and invasion by colocalizing and interacting
with liprin a1 at the lamellipodia and downregulating
the expression and activity of MMP-2 and MMP-9.
16,21,34
These findings revealed that ING4 as a potent tumor
suppressor negatively modulates tumor growth via multi-
ple pathways.
Chemotherapy is one of the commonly used strategies
in HCC treatment, especially for unresectable patients.
Conventional chemotherapy drugs often have severe side
effects that limit their efficacy. Moreover, tumor cells are
able to acquire resistance to chemotherapy. The increased
dose of chemotherapy drug that is necessary to overcome
resistance of tumor cells, even a small increase, may result
in severe cytotoxicity to normal cells. Therefore, it is
urgent to explore novel approaches to broaden the
application of the chemotherapy drug in cancer therapy.
To enhance therapeutic effect, eliminate drug resistance
and reduce side effects, several conjugated strategies such
as the combined treatment of gene therapy and con-
ventional chemotherapy (chemo-gene therapy) have
been applied successfully in cancer chemotherapy. Our
previous studies demonstrated that Ad-ING4 gene
transfer can induce growth inhibition and apoptosis in
human lung and pancreatic carcinoma cells.
21,22 A recent
study has shown that ING4 can enhance chemosensitivity
to doxorubicin and etoposide in HepG2 hepatocarcinoma
cells,
19 suggesting that it may be used as a chemosensitive
modulator in the combination therapy with chemotherapy
Figure 5 Synergistic inhibition of tumor angiogenesis in vivo.( a) Immunohistochemical detection for CD34 expression in SMMC-7721
hepatocarcinoma s.c. xenografted tumors. Representative pictures for different treatment groups are shown. The positive expression of CD34
was mainly represented as brownish yellow or brownish granules in tumor vascular endothelial cells. (b) The tumor MVD in different treatment
groups. Ad-ING4 plus CDDP combination treatment synergistically inhibited in vivo angiogenesis of SMMC-7721 hepatocarcinoma s.c.
xenografted tumors (*Po0.05, compared with Ad-GFP and PBS group, one-way repeated measures ANOVA and multiple comparisons, n¼6
mice per condition, n¼5 observations per representative section;
#CI in the Ad-ING4 plus CDDP combination treatment 41). Data shown are
representative of three independent experiments.
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therapy and CDDP, an attractive chemotherapy drug, on
human cancers, is still unknown. Therefore, in this study,
we were interested in addressing the therapeutic effect
of chemo-gene therapy by combining Ad-ING4 with
CDDP on human hepatocarcinoma cells in vitro and
in vivo in an athymic nude mouse model and its potential
mechanism.
Before initiating in vitro combination therapy, we first
assessed the cytotoxic effect of Ad-ING4 or CDDP alone
on SMMC-7721 and HepG2 hepatocarcinoma cells and
HL-7702 normal liver cells. We found that Ad-ING4
significantly inhibited SMMC-7721 human hepatocarci-
noma cell growth, whereas it moderately inhibited HepG2
hepatocarcinoma cell growth. However, Ad-ING4 had
only a minimal effect on HL-7702 normal human liver
cells, indicating that transgene ING4 overexpression
exerts selective tumor-killing activity in hepatocarcinoma
cells. In addition, chemotherapy drug CDDP induced a
dose-dependent growth inhibition in SMMC-7721 and
HepG2 hepatocarcinoma cells or HL-7702 normal liver
cells. Furthermore, the HepG2 hepatocarcinoma cells
were more sensitive to CDDP than SMMC-7721 hepato-
carcinoma cells. Different tumor cell lines are different in
their susceptibility to drugs. In this study, the HepG2 and
SMMC-7721 hepatocarcinoma cell lines are both adher-
ent and epithelial-like cells, but from different origins.
The former was established from the tumor tissue of a
15-year-old Argentine boy with HCC in 1975, which was
reported to produce a variety of proteins such as alpha-
fetoprotein, albumin, alpha2-macroglobulin, alpha1-anti-
trypsin and transferrin. The latter was established from
the tumor tissue of a 56-year-old Chinese man with HCC
in 1980. The different origins and different biological
activities may be one of the reasons for the different
susceptibility to Ad-ING4 and CDDP. In addition, higher
concentration of CDDP (6 or 12mgml
 1) exhibited
significant growth-suppressive effect on HL-7702 normal
liver cells, while 3mgml
 1 of CDDP only induced slight
cytotoxicity. To minimize toxicity to normal cells and
produce only modest antitumor efficacy when used as
monotherapy, while leaving a window for observation of
additive or synergistic effects of Ad-ING4 plus CDDP
combination therapy, we selected the relatively non-
sensitive hepatocarcinoma cell line to CDDP, SMMC-
7721, and the optimal dose of 1.5mgml
 1 of CDDP in the
in vitro combination treatment. We demonstrated that
Ad-ING4 plus CDDP combination treatment selectively
exerted in vitro synergistic therapeutic activity in SMMC-
7721 hepatocarcinoma cells, but not in HL-7702 normal
liver cells. Moreover, treatment of SMMC-7721 hepato-
carcinoma cells with Ad-ING4 plus CDDP resulted in
enhancement of apoptosis. To further address the under-
lying mechanism involved in Ad-ING4 plus CDDP-
induced enhanced antitumor activity, the expression of
apoptosis-related proteins such as Fas, caspase-8, Bid,
Bcl-2, Bcl-XL, Bax, Bak, caspase-9, caspase-3 and PARP
in different treatments of SMMC-7721 hepatocarcinoma
cells was assessed by western blot analysis. Fas as an
important apoptotic marker has been shown to regulate
FasL–Fas extrinsic apoptotic pathway.
35 Associated with
the increase in Fas expression is the cleavage of Caspase-8
and Bid, downstream targets of Fas, that have a
important role in the extrinsic apoptotic pathway.
35
Moreover, caspase-8-mediated cleavage of Bid, which
translocates to the mitochondria, also results in the
activation of intrinsic apoptotic pathway.
36,37 Bcl-2
protein family is known to be a key regulator of apoptosis
and an important determinant of cell fate.
38 The ratio of
anti- to pro-apoptotic molecules (Bcl-2, Bcl-XL; Bax,
Bak) constitutes a rheostat that sets the threshold of
susceptibility to apoptosis for the intrinsic apoptotic
pathway, which promotes pore formation in the mito-
chondrial outer membrane leading to loss of mitochon-
drial integrity and the release into the cytosol of
cytochrome c followed by the activation of caspase-9,
caspase-3 and cleavage of downstream substrate
PARP.
38,39 Western blot results showed that Ad-ING4
plus CDDP combination treatment elicited an additive
effect on the altered expression of apoptosis-related
proteins, leading to the cooperative activation of extrinsic
and intrinsic apoptotic pathways, which may closely
account for the Ad-ING4 plus CDDP-mediated synergis-
tic growth inhibition and apoptosis in SMMC-7721
hepatocarcinoma cells. In the in vivo combination
treatment, a CDDP-dose-finding study was also primarily
performed in SMMC-7721 human hepatocarcinoma s.c.
xenografted tumor-bearing athymic nude mice by i.p.
injection with various doses of CDDP. Mice treated with
higher CDDP doses (5 or 10mgkg
 1) caused significant
toxicity, while those treated with 1 or 3mgkg
 1 of CDDP
showed only minimal toxicity. Moreover, tumor progres-
sion was significantly retarded in the mice treated with
3mgkg
 1 of CDDP, but moderately retarded in those
treated with 1mgkg
 1 of CDDP. Therefore, an optimal
dose of 1mgkg
 1 of CDDP was selected for the in vivo
combination treatment. We demonstrated that Ad-ING4
plus CDDP also synergistically suppressed in vivo
SMMC-7721 hepatocarcinoma s.c. xenografted tumor
growth in an athymic nude mouse model without additive
toxicity in vivo. The progressive growth and metastasis of
solid tumors is dependent on the process of angiogen-
esis.
40,41 Tumor angiogenesis has a critical role in the
development and progression of HCC. It has been shown
that ING4 can suppress tumor angiogenesis by inhibiting
the activity of NF-kB and HIF-1a.
13,20 It has also been
demonstrated that CDDP can exert a potent antiangio-
genic activity during CDDP-based cancer chemother-
apy.
42,43 To explore the combined effect of Ad-ING4 plus
CDDP on tumor angiogenesis in vivo, the MVD in
SMMC-7721 hepatocarcinoma xenografted tumor tissues
was determined by CD34 immunohistochemistry analysis.
We further found that Ad-ING4 plus CDDP synergisti-
cally downregulated CD34 expression and suppressed
angiogenesis in SMMC-7721 hepatocarcinoma s.c. xen-
grafted tumors, which may be another important
mechanism involved in Ad-ING4 plus CDDP-mediated
in vivo synergistic growth inhibition of SMMC-7721
hepatocarcinoma xenografted tumor in an athymic nude
mouse model.
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Cancer Gene TherapyTaken together, Ad-ING4 plus CDDP combined
treatment resulted in in vitro and in vivo synergistic
growth inhibition, enhanced apoptosis, had an additive
effect on upregulation of Fas, Bax, Bak, cleaved Bid,
cleaved caspase-8, caspase-9, caspase-3 and cleaved
PARP, and on downregulation of Bcl-2 and Bcl-XL in
SMMC-7721 hepatocarcinoma cells, and synergistically
reduced CD34 expression and MVD in SMMC-7721
hepatocarcinoma s.c. xenografted tumors. Most impor-
tantly, the combination of Ad-ING4 with CDDP did not
have overlapping toxicities in in vitro HL-7702 normal
liver cells and in vivo normal liver tissues of mice. The
enhanced antitumor effect in vitro and in vivo elicited by
Ad-ING4 plus CDDP was closely associated with the
increased Fas expression and cleavage of Caspase-8 and
Bid, and decrease in the ratio of anti to pro-apoptotic
molecules (Bcl-2, Bcl-XL; Bax, Bak) followed by activa-
tion of Caspase-9 leading to Caspase-3 activation and
apoptosis by cooperatively regulating extrinsic and
intrinsic apoptotic pathways, and the in vivo synergistic
inhibition of tumor angiogenesis. Thus, our results
indicate that Ad-ING4 plus CDDP is a potential
combined treatment strategy for hepatocarcinoma.
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